| Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study | |
| Hou, Jian*; Jin, Jie; Xu, Yan; Wu, Depei; Ke, Xiaoyan; Zhou, Daobin; Lu, Jin; Du, Xin; Chen, Xiequn; Li, Junmin | |
| 刊名 | Journal of Hematology & Oncology
 |
| 2017 | |
| 卷号 | 10期号:1页码:137 |
| 关键词 | China Ixazomib Multiple myeloma Oral Overall survival Progression-free survival Proteasome inhibitor Relapsed/refractory |
| ISSN号 | 1756-8722 |
| DOI | 10.1186/s13045-017-0501-4 |
| URL标识 | 查看原文 |
| WOS记录号 | WOS:000404855200001;PMID:28683766 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3341646 |
| 专题 | 中南大学 |
| 作者单位 | [Hou, Jian] Second Mil Med Univ, Chang Zheng Hosp, Dept Hematol, Shanghai 200003, Peoples R China. |
| 推荐引用方式 GB/T 7714 | Hou, Jian*,Jin, Jie,Xu, Yan,et al. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study[J]. Journal of Hematology & Oncology,2017,10(1):137. |
| APA | Hou, Jian*.,Jin, Jie.,Xu, Yan.,Wu, Depei.,Ke, Xiaoyan.,...&Moreau, Philippe.(2017).Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.Journal of Hematology & Oncology,10(1),137. |
| MLA | Hou, Jian*,et al."Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study".Journal of Hematology & Oncology 10.1(2017):137. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论